News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've followed these criminal reverse splits for 3+years and 99.99% of them never recover. They tank right back down the the pps they were at when split. Shareholders lose every dime they had. I've heard that "We did the huge reverse split to move up to NASDAQ" BS so damn many times it's laughable. If these clowns had some cancer cure then they don't need to worry about pulling a 1 for 60,000 RS. The revised share structure still isn't on OTC Markets. But when it is just watch how fast the DUMPING starts.
When they take 60,000 shares away from you then give you one back it's is CRIME. It's done with NO guarantee's for shareholders after stealing shares. Just like this stock,it RS to $25.00 and it's TANKED to $10.00. That's a 60% loss in just 5 trading days.
So with an OS of 13,300 approx. Surely worth $7......for now . $PPCB
|
Followers
|
418
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
49427
|
|
Created
|
05/18/14
|
Type
|
Free
|
| Moderators | |||
This section maintained by INV4
Offering New Hope to Cancer Patients and Their Caregivers
| About Propanc Biopharma, Inc. The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. A Long-Term Therapy Based on a Pancreatic Proenzyme Formulation Developing Long-Term Therapy for the Treatment of Solid Tumors Technology Based on Pancreatic Proenzyme Therapy Treatments that Inhibit Tumor Growth and Metastasis Our Lead Product: PRP Technology Based on Pancreatic Enzyme Therapy More than one hundred years ago, Professor John Beard first proposed that the pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard´s hypothesis with encouraging data from patient treatment. |
Click here for the video (with sound)
====================== PPCB SECURITY DETAILS ======================
Share Structure
Market Cap | 1,652,679 | 02/27/2023
Authorized Shares | 10,000,000,000 | 02/13/2023
Outstanding Shares | 1,836,310,391 | 02/13/2023
Restricted | 194,354,827 | 02/13/2023
Unrestricted | 1,641,955,564 | 02/13/2023
Held at DTC | 1,641,916,456 | 02/13/2023
| Board of Directors James Nathanielsz has served as a director and Chief Executive Officer of our company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an anti-infective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the Co-Founder of Propanc and for his experience in R&D and manufacturing and distribution. Mr. Nathanielsz holds a B.App.Sci in Biochemistry/Applied Chemistry and an M.E.I. from Swinburne University of Technology in Melbourne, Australia. ============== Dr. Julian Kenyon founded our company and was appointed as a director on February 12, 2008. Since 2000, Dr. Kenyon has served as an integrated medical physician and Medical Director of the Dove Clinic for Integrated Medicine in Winchester and London. He was the Founder-Chairman of the British Medical Acupuncture Society in 1980 and Co-Founder of the Centre for the Study of Complementary Medicine in Southampton and London. Dr. Kenyon was selected as a director because he is the Co-Founder of the Australian subsidiary and the business is based on his initial work at the Dove Clinic. Dr. Kenyon holds an M.B.Ch.B. and M.D. from the University of Liverpool Since 1972, he was appointed a Primary Fellow of the Royal College of Surgeons, Edinburgh. ============== Mr Zelinger is a Certified Practicing Accountant with 45 years of experience in tax, auditing, finance, investment and management consulting. Mr Zelinger also has significant expertise in property management and import/export businesses. Mr Zelinger commenced his career as an accountant at L.M. Stanton & Partners - Chartered Accountants, subsequently joining Caston Pty Ltd in 1980, a steel manufacturer as Chief Financial Officer, and Company Director, until 1983. Since the mid-1980’s until current date, Mr Zelinger serves as Director in several private investment companies in a range of businesses including property portfolio manager of commercial real estate, import/export businesses and a range of commercial and financial investment companies. Since 1980, Mr Zelinger also operates as a sole practitioner in accountancy and tax consulting. In 1973, Mr Zelinger graduated in Accounting and admitted as a Fellow of RMIT University in Business. He has been a Certified Practicing Accountant since 1984. Mr. Zelinger is a shareholder of Propanc Biopharma Inc. since 2010. ======================================================================== Company Info Industry Classifications |
AI
